Read article New Agents Committee Trials Funding
The New Agents Committee (NAC) funding scheme provides a one-step process for selecting new anti-cancer treatments and diagnostics and taking them into early clinical trials.
The NAC was set up by Cancer Research UK's Drug Development Office (DDO).
The NAC meets three times a year and comprises clinicians expert in early clinical trials of novel agents as well as other experts in drug development.
Eligibility
Applications must be submitted via our electronic Grants Management System (eGMS). See How to apply for more information and to submit your application via eGMS.
NAC Trial Grant or Trial Endorsement applications will only be accepted from individuals based in UK academic institutions.
DDO Project proposals can be made by individuals based in academic institutions and industry collaborators worldwide.
Trials are only carried out in the UK and grant funding is only awarded to UK academic institutions.
Where a grant is part of the proposal, applicants should refer to the standard Cancer Research UK funding Terms and conditions.
Period of funding
NAC Trial Grants are funded for two years.
For DDO Project proposals, a project budget and DDO staff to manage the development process are allocated for the duration required to develop the agent and undertake the trial.
Funding value
For NAC Trial Grants - £40,000 per annum.
For DDO Projects - no set value. NAC decisions are made on the basis of scientific and clinical merit, and development budgets are allocated as required. The DDO prepares a resource paper with estimated costs following discussions with the applicant.
How to apply
Applications must be submitted via our electronic Grants Management System (eGMS). See How to apply for more information and to submit your application via eGMS.
NAC Trial Grants or NAC Endorsement: you will need to submit a draft trial protocol in addition to the forms on eGMS. Applicants who are unsure whether NAC is the appropriate funding scheme should complete the one page New trial summary proforma (PDF, 111KB) and email it to Kate Searle for confirmation.
DDO Projects: you will need to submit supporting data in addition to the forms on eGMS. Before applying, applicants should email a brief project outline to Dr Ola Zaid in the Clinical Partnerships Team for an informal discussion. The outline should include, if possible:
- Project background and stage of development;
- Nature of agent(s) (e.g. small molecule, antibody, cell or gene therapy) and any information on manufacture /production and physicochemical properties;
- Target and rationale;
- Any in vitro and in vivo data, including; mechanism of action, efficacy, toxicology, PK/PD and, if appropriate, combination data;
- Summary of studies proposed (non-clinical, clinical);
- Summary of IP if known.
The DDO provides advice on whether your DDO Project proposal is ready to be submitted to the NAC. Relevant issues include the novelty and strength of the scientific rationale, the completeness of the data package, and the nature of the proposed clinical trial.
Submission deadlines
| Preliminary submissions | Final submissions | Committee review |
|---|---|---|
| N/A | 19 Jul 2013 | Oct 2013 |
Additional notes
All NAC proposals and meetings are confidential.
DDO Project applicants are invited to attend the NAC meeting to address any questions or issues that the Committee raise.
Increase text size
Decrease text size
Print page
